Table 2 Clinical characteristics
Characteristic | Count |
|---|---|
Total Patients | 761 |
  Baseline Clinical Characteristics |  |
  Charlson Comorbidity Index* | 1.1 (± 1.6) |
| Â | 1 [0 - 12] |
  Osteoporosis Drug Utilization in Pre-Period n,(%) | 353 (46.4%) |
    Bisphosphonate n,(%) | 283 (80.2%) |
    Calcitonin n,(%) | 39 (11.0%) |
    Selective Estrogen Receptor Modulator (SERM) n,(%) | 42 (11.9%) |
    Conjugated Estrogen n,(%) | 22 (6.2%) |
  Fracture in the 6 Month Pre-Period n, (%) | 386 (50.7%) |
  Fracture in the 12 Month Pre-Period n,(%) ** | 443 (58.2%) |
  Comorbidity (Top 10 Identified) n, (%)†|  |
  Other disorders of bone and cartilage (733.) | 752 (98.8%) |
  Essential hypertension (401.) | 546 (71.7%) |
  Disorders of lipid metabolism (272.) | 529 (69.5%) |
  General symptoms (780.) | 474 (62.3%) |
  Other and unspecified disorders of back (724.) | 402 (52.8%) |
  Symptoms involving respiratory system and other chest symptoms (786.) | 391 (51.4%) |
  Other and unspecified disorders of joint (719.) | 382 (50.2%) |
  Osteoarthritis and allied disorders (715.) | 361 (47.44%) |
  Other disorders of soft tissues (729.) | 333 (43.8%) |
  Cataract (366.) | 281 (36.9%) |
  Post-Period Clinical Characteristics |  |
  Fracture in the 12 Month Post-Period n,(%) | 222 (29.2%) |
  Time Between Index Date and First Fracture (Days)* | 200 (± 81) |
| Â | 181 [91 - 364] |
  Proportion of Days Covered (PDC) Between Index Date and First Fracture* | 0.46 (± 0.3) |
| Â | 0.38 [0.08 - 1.0] |
  Reached Part D Coverage Gap During 12 Month Follow-up Period n, (%) | 586 (77%) |
  Out of Pocket Cost for All Prescription Claims During 12 Month Follow-up | $2,082 (± $2,189) |
  Period* | $991 [$30 - $10,894] |
  Out of Pocket Cost for Teriparatide Prescription Claims During 12 Month | $1,247 (± $1,832) |
  Follow-up Period* | $228 [$15 - $7,165] |